InvestorsHub Logo
Followers 7
Posts 787
Boards Moderated 0
Alias Born 03/03/2008

Re: slunj post# 1702

Thursday, 06/20/2019 11:26:37 AM

Thursday, June 20, 2019 11:26:37 AM

Post# of 3536
To your "small" points slunj:
With products such as the G7, Dexcom is beginning to run up against some of the limits of miniaturization and balancing technology, usability, and cost.


Kevin Sayer, Dexcom President and CEO

One of the challenges that many people with diabetes need to face is dexterity and usability. As components and devices get smaller and lower-profile, they may become more difficult for some people to use, or more delicate overall.

In addition, there’s the issue of power generation and consumption, and how that relates to device construction. For example, Sayer points out, the battery fueling the G6 transmitter actually generates enough power to run for three months – yet the sensor itself only runs for about two weeks, due to the fundamental limits behind the chemistry and biology of glucose sensing technology.

“As we look at in the future, to G7 and past G7, if you look at the electronics innovations coming – there are flexible batteries or even smaller power sources, “ said Sayer. “We have some interesting decisions to make in the future. How small does it really have to be?”&
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent KNW News